Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Lumos Pharma Inc (LUMO)

Lumos Pharma Inc (LUMO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,264
  • Shares Outstanding, K 8,396
  • Annual Sales, $ 230 K
  • Annual Income, $ -30,430 K
  • 60-Month Beta 0.94
  • Price/Sales 162.81
  • Price/Cash Flow N/A
  • Price/Book 0.55
Trade LUMO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.96
  • Number of Estimates 5
  • High Estimate -0.87
  • Low Estimate -1.03
  • Prior Year -0.68
  • Growth Rate Est. (year over year) -41.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.52 +2.84%
on 12/09/22
9.15 -60.44%
on 11/10/22
-5.33 (-59.55%)
since 11/09/22
3-Month
3.52 +2.84%
on 12/09/22
9.56 -62.13%
on 09/22/22
-5.12 (-58.58%)
since 09/09/22
52-Week
3.52 +2.84%
on 12/09/22
10.27 -64.75%
on 02/14/22
-3.51 (-49.23%)
since 12/09/21

Most Recent Stories

More News
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LUMO : 3.62 (-13.81%)
CUE : 3.14 (-3.09%)
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LUMO : 3.62 (-13.81%)
TCRX : 2.04 (-2.86%)
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials...

LUMO : 3.62 (-13.81%)
Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?

Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LUMO : 3.62 (-13.81%)
CSTL : 22.32 (-8.56%)
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...

LUMO : 3.62 (-13.81%)
Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?

Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

LUMO : 3.62 (-13.81%)
IMRX : 5.18 (-4.60%)
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?

Amryt Pharma PLC Sponsored ADR (AMYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...

AMYT : 7.10 (+1.00%)
LUMO : 3.62 (-13.81%)
Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for...

LUMO : 3.62 (-13.81%)
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA...

LUMO : 3.62 (-13.81%)
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA...

LUMO : 3.62 (-13.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics...

See More

Key Turning Points

3rd Resistance Point 4.87
2nd Resistance Point 4.68
1st Resistance Point 4.44
Last Price 3.62
1st Support Level 4.01
2nd Support Level 3.82
3rd Support Level 3.58

See More

52-Week High 10.27
Fibonacci 61.8% 7.69
Fibonacci 50% 6.90
Fibonacci 38.2% 6.10
Last Price 3.62
52-Week Low 3.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar